Osiris Therapeutics, Inc. (OSIR)
-NasdaqGM 11.02 
0.05(0.45%) 4:00PM EDT|After Hours
:
11.02 0.00 (0.02%) 4:35PM EDT
| Prev Close: | 11.07 |
|---|
| Open: | 11.17 |
|---|
| Bid: | 7.00 x 200 |
|---|
| Ask: | 11.42 x 500 |
|---|
| 1y Target Est: | 8.50 |
|---|
| Beta: | 1.81 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 10.90 - 11.18 |
|---|
| 52wk Range: | 6.00 - 14.46 |
|---|
| Volume: | 51,085 |
|---|
| Avg Vol (3m): | 139,212 |
|---|
| Market Cap: | 362.90M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.38 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- OSIRIS THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Pipeline Progress at GileadZacks(Thu, May 16)
- OSIRIS THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Is the Golden Age of Blockbusters Over?at Motley Fool(Thu, May 9)
- Osiris Loss In-Line with ExpectationsZacks(Wed, May 8)
- Safe Stem Cell Therapy for Healing Is Still a Strong Betat Motley Fool(Tue, May 7)
- Osiris Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 7)
- Osiris Therapeutics price target raised to $14 from $11.50 at Piper Jaffraytheflyonthewall.com(Tue, May 7)
- Osiris CEO: Our Stem Cell Drug With Zero Sales Is Widely Usedat TheStreet(Tue, May 7)
- Osiris Therapeutics Announces First Quarter 2013 Financial ResultsBusiness Wire(Tue, May 7)
- Q1 2013 OSIRIS THERAPEUTICS INC Earnings Release - Before Market OpenCCBN(Tue, May 7)
- OSIRIS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Tue, May 7)
- Loss at Aegerion Narrower Than ExpectedZacks(Fri, May 3)
- Athersys Has Some Promise, But Controversy And Doubt Remainat Seeking Alpha(Thu, May 2)
- Convenience is Key in Cell Therapy Products: An Expert Analyst Discusses His Coverage of the Oncology and Cell Therapy Spaces with The Wall Street TranscriptWall Street Transcript(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 31.80 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.31 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.09 |
|---|
| Mean Recommendation*: | 3.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat medical conditions in the inflammatory, cardiovascular, orthopedic, and wound healing markets.
View More